IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.67▼ 0.02% USD/MXN18.57▲ 0.34% USD/CLP994.16▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN3.41▲ 0.17% USD/ARS1,544▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB 11.59 — 0.00% USD/DOP 60.59 — 0.00% USD/CRC442.74— 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES911.74▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69— 0.00% USD/TTD6.75— 0.00% EUR/BRL6.25▼ 0.04% BRENT 92.94 ▼ 3.03% WTI 88.61 ▲ 0.06% IRON ORE 161.91 — — COPPER 6.03 ▼ 0.78% GOLD 3,866 ▼ 0.52% SILVER 47.52 ▼ 3.08% SOY 1,230 ▼ 1.09% CORN 445.50 — 0.00% WHEAT 591.25 ▼ 0.34% COFFEE 281.95 ▲ 1.18% SUGAR 18.31 ▼ 0.54% ORANGE JUICE 136.85 ▼ 2.91% COTTON 81.40 ▲ 3.33% COCOA 5,181 ▲ 1.21% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.67 ▼ 0.02% USD/MXN 18.57 ▲ 0.32% USD/CLP 994.16 ▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN 3.41 ▲ 0.18% USD/ARS 1,544 ▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB 11.59 — 0.00% USD/DOP 60.59 — 0.00% USD/CRC 442.74 ▲ 1.24% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES 911.74 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.75% USD/TTD 6.75 ▲ 2.58% EUR/BRL 6.25 ▼ 0.04% BRENT 92.94 ▼ 3.03% WTI 88.61 ▲ 0.06% IRON ORE 161.91 — — COPPER 6.03 ▼ 0.78% GOLD 3,866 ▼ 0.52% SILVER 47.52 ▼ 3.08% SOY 1,230 ▼ 1.09% CORN 445.50 — 0.00% WHEAT 591.25 ▼ 0.34% COFFEE 281.95 ▲ 1.18% SUGAR 18.31 ▼ 0.54% ORANGE JUICE 136.85 ▼ 2.91% COTTON 81.40 ▲ 3.33% COCOA 5,181 ▲ 1.21% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00%
since 2009
Monday, November 16, 2026

Brazil Business - Brazil

Drug that eliminates cancer in 100% of cases arrives in Brazil this year

By · · 2 min read

RIO DE JANEIRO, BRAZIL – Dostarlimab, an experimental drug that could eliminate cancer in 100% of the cases in an American study, should be available in Brazil in August this year, according to the pharmaceutical company GSK Brasil. The drug already has approval from Anvisa.

The monoclonal antibody was used intravenously in the test to treat colorectal tumors. Within six months of taking the drug, the patients’ cancer had disappeared without needing chemotherapy or surgery. The results were presented in the New England Journal of Medicine.

In Brazil, however, the drug is released only to treat a rare type of recurrent or advanced endometrial cancer (tissue lining the inner wall of the uterus) with repair enzyme deficiency (dMMR) or high microsatellite instability (MSI-H) that has progressed during or after platinum-containing chemotherapy.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.
The 12 people involved in the trial get rid of the disease and show no traces of cancer anywhere in their bodies, but they suffered no serious adverse effects.
The 12 people involved in the trial got rid of the disease and show no traces of cancer anywhere in their bodies, but they suffered no serious adverse effects.
RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

In an interview with The New York Times, oncologist Luiz Diaz Jr, one of the paper’s authors and Chief of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, said the success rate of the U.S. research is unusual and may be the first time anything like this has been recorded in the entire history of cancer studies.

WHAT IS DOSTARLIMAB?

The drug is a checkpoint inhibitor monoclonal antibody designed to induce immune cells to recognize and attack cancer cells. It was first approved in the United States for use as a cancer treatment in early 2021.

Not only did the 12 people involved in the trial get rid of the disease and show no traces of cancer anywhere in their bodies, but they suffered no serious adverse effects.

The drug, which goes by the trade name Jemperli, comes in a vial, and its contents are injected intravenously (into a vein) over 30 minutes by a doctor or nurse at a medical center or infusion center.

It is usually administered once every three weeks for four cycles and then once every six weeks, according to medical protocol.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.